Search results
Aug 23, 2023 · Tofacitinib is available in the form of a tablet (Xeljanz), an extended release tablet (Xeljanz XR) and as an oral solution. It is used to treat certain inflammatory conditions in people who have already tried tumor necrosis factor (TNF) blockers.
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis.
Jun 25, 2024 · Xeljanz (tofacitinib citrate) is a Janus kinase (JAK) inhibitor and disease modifying anti-rheumatic drug (DMARD), which works by suppressing the immune system. Continue reading
Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis -pcJIA). It...
Adults—22 milligrams (mg) once a day for at least 8 weeks, then 11 mg once a day. Your doctor may adjust your dose as needed. Children—Use and dose must be determined by your doctor. For oral dosage form (tablets): Adults—10 milligrams (mg) 2 times a day for at least 8 weeks, then 5 or 10 mg 2 times a day.
Jul 3, 2023 · Tofacitinib is FDA approved for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PA), ulcerative colitis (UC), and polyarticular course juvenile idiopathic arthritis (pcJIA). It is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme.
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.
